It demonstrated its capabilities by identifying well-documented associations in TCGA CRC datasets, such as the enrichment of TP53 mutations in late-stage CRC and the association of KRAS mutations with poor progression-free survival in FOLFOX-treated patients. Here, KRAS is linked to colorectal carcinoma.